Research programme: hydrogen sulfide-based therapeutics - Antibe Therapeutics

Drug Profile

Research programme: hydrogen sulfide-based therapeutics - Antibe Therapeutics

Alternative Names: Aspirin derivative - Antibe Therapeutics; ATB 340; ATB-282; ATB-284; ATB-352; ATB-427; ATB-428; ATB-429

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antibe Therapeutics
  • Class Analgesics; Anti-inflammatories; Anticoagulants; Sulfides
  • Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Blood coagulation disorders
  • No development reported Acute pain; Inflammatory bowel diseases; Irritable bowel syndrome

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute pain in Canada
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Canada
  • 27 Oct 2016 Antibe Therapeutics plans a preclinical toxicology trial for Acute pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top